Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female adult (≥18 years old) hospitalized patients with respiratory tract diseases and abnormal mucus secretions such as: acute bronchitis, chronic bronchitis and exacerbations, emphysema, mucoviscidosis and bronchiectasis.~2. Chinese ethnicity and/or Chinese~3. Signed the informed consent form before any study-related procedure~4. Sputum viscosity score ≥ 2 at randomization visit~5. Expectoration difficulty score ≥ 2 at randomization visit~6. Willingness and ability to comply with study procedures~Exclusion Criteria:~1. Intolerance or contra-indication to treatment with NAC or ambroxol or allergy to any component of the study treatments~2. (For female patients) ongoing pregnancy or lactation, or childbearing potential but unwillingness to adopt abstinence or contraception measures during the study~3. Intake of an investigational drug within 1 month before the screening visit~4. Use of expectorants or drugs with expectorant effect within 2 days before randomization visit~5. Diagnosis of active tuberculosis, lung cancer, pulmonary fibrosis, acute pulmonary thromboembolism or any other respiratory condition that might, in the opinion of the investigator, compromise the safety of the patient or affect the interpretation of the results~6. Medical history of and/or illness (including laboratory abnormality) and/or treatment that in the investigator's opinion may interfere with the patient's safety, compliance, or study evaluations~7. Serum alanine aminotransferase and/or aspartate transaminase more than 3 times above the upper limit of normal at screening visit~8. Serum creatinine more than 3 times above the upper limit of normal at screening visit~9. Addiction to alcohol or drugs~10. Mental illness, or other reasons for non-cooperation in the investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active test treatment-NAC (Type: EXPERIMENTAL): NAC 600mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
- Active control treatment-Ambroxol hydrochloride (Type: ACTIVE_COMPARATOR): Ambroxol hydrochloride 30 mg will be administered by slow intravenous infusion twice daily for the 1-week treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered by slow intravenous infusion twice daily for the 1-week treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).